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about the cover:
Penn Vet researchers at Pennsylvania’s Equine Toxicology Laboratory have developed the premier program
for effective testing for artificial substances such as steroids. Read about their work starting on page 4.
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How Penn Vet Researchers Put
the Brakes on PerformanceEnhancing Drugs in Racehorses
By Susan I. Finkelstein

B

uilding a faster racehorse: the dream of
horsemen for hundreds of years, back to the
days when horseracing was considered the
sport of kings. As early as 1140, Henry I tried
to make his “hobby horses” faster and stronger
by breeding them with Arab stallions brought
from the Crusades. Obviously, selective breeding has come
a long way in the intervening centuries toward increasing a
horse’s natural speed and endurance, but a modern phenomenon
called “doping”— illegal application of a substance to improve
a horse’s natural capacities at the time of a race—famously used
by human athletes, has become a shortcut of choice to create
a winning horse. Traditionally, the most commonly abused
substances in horseracing have included anabolic steroids,
etorphine, narcotic analgesics, erythropoietin (EPO), caffeine,
beta blockers, butazolidin, bicarb and propantheline bromide.
All these (along with hundreds of others) have been banned,
and even substances not on the prohibited list of the Association
of Racing Commissioners International cannot be administered
on race day, or sometimes for up to even 30 days before a race.
Enforcement of the ban requires effective monitoring, detection,
identification and confirmation methods. Enter Dr. Lawrence
R. Soma, V’57, Marilyn M. Simpson Professor of Large
Animal Veterinary Medicine, and Dr. Cornelius E. Uboh,
adjunct associate professor of pharmacy and pharmacology
and director of the Pennsylvania Equine Toxicology and
Research Laboratory (PETRL) in West Chester, Pa.

{

In 2006, Drs. Soma and Uboh and their colleagues
at Penn Vet and PETRL became the first in
the world to develop a method for confirming
blood-doping agents—recombinant human
erythropoietin (rhEPO) and darbepoetin-alfa
(DPO)—in equine athletes by testing plasma
through liquid chromatography (separation) and
mass spectrometry (identification). Previously,
only the antibodies caused by the drug—not the
drug itself—were detectable in the blood. Used
in human and small animal veterinary medicine
to treat conditions that produce anemia such
as cancer, and renal disease, EPO is a natural
hormone protein produced in the kidneys that
stimulates red blood cell production; rhEPO and
DPO are genetically engineered versions of EPO.
These synthetic agents have been abused in human
endurance sports and horseracing because they are
difficult to detect and they increase hemoglobin,
hematocrit concentration (the ratio of the volume
of packed red blood cells to that of whole blood)
and maximal oxygen uptake (since red blood
cells carry oxygen)—hence improving speed and
endurance time. Not only does use of these agents
violate rules of fair competition, but deaths in
equine and human athletes also have been linked to
them. The potential harmful effects they may have
on the health of horses are still being investigated,
but because they are made from human EPO they
are foreign proteins being administered to animals.
In other words, they do not naturally belong there.
One result? “The horses make antibodies
against the drug. There have been a number of
deaths because they have been given multiple
doses,” said Dr. Soma. “Multiple doses in
one animal seem to build up a resistance that
suppresses its own naturally occurring [equine]
EPO, and produces antibodies that can be
identified, so when you take it away, the horse
suddenly can become very anemic and crashes.
There have been some DNA changes, genetic
changes in the proteins, some amino acid
changes, endogenous changes, but we haven’t
been able to figure that out completely yet.”
Although long-term deleterious effects of
the administration of the human-protein–based
drugs on horses are still being determined,
the immediate impact of a positive bannedsubstance test on the winners’ purses are very
much known. In Pennsylvania, blood and urine

Dr. Lawrence R. Soma, V’57. Photo by Sabina Louise Pierce.

from all first-place winners and horses randomly
selected at the commonwealth’s six racetracks
are drawn automatically. The laboratory also
receives anonymous samples for testing. If a
horse tests positive, its race victory is voided,
and the winning purse—which can range from
$5,000 to $500,000 or more—is awarded to the
next finisher. In addition to affecting the bottom
line, violators can also face fines, suspension
and even license revocation. Inevitably, with
such high stakes come increasingly sophisticated
methods by cheaters to beat the system.
“We call them ‘basement chemists.’ They are
advising the horsemen on what to do,” explained
Dr. Uboh. “Yes, it is a great challenge for us
to keep up with the new designer drugs being
illegally developed. We are working within the
legal system, meaning that we are looking for
drugs approved for use; those are the standards we
have. We can go to the market and buy those,
but the ones synthesized in basements are not
publicized, are not out there on the market. We
can’t buy them. So that’s a challenge we face.”

{The Decline of Steroids

{

{ The 411 on EPO

Because anabolic steroids have become very easy
to detect via today’s testing protocols, their abuse
in horseracing has rendered them largely a thing
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answer or identify that peak instead of wasting
time on so many irrelevant peaks or signals.”
Dr. Soma believes most horsemen are
glad about the ban. “I think if you talk to the
average trainer now, he is happy with the ban
because he says, ‘Now, it’s a level playing field.
I know my neighbor. He doesn’t have a
competitive edge on me because he can give
an anabolic steroid and I don’t want to.’
Some trainers didn’t want to give steroids
but felt forced to because they wouldn’t
have had that same competitive edge.”
Aside from the unfair impact anabolic steroids
had on racing, the chemicals also seemed to
have negative effects on the animals’ behavior,
akin to the “’roid rage” that can occur in people
using the substances. “That’s why they’ve been
banned, finally—because they caused behavioral
changes,” Dr. Soma explained. “We started
looking at anabolic steroids about six years ago
now. The racing commission veterinarians were
saying, ‘I’ve got horses I can’t handle.’ They
were having females act like males. If you give
testosterone to a female, put her out in the
pasture and there’s another female out there,
she’s going to act like a stud. And if a gelding is
given testosterone, he’s going to act like a stud.”

{PETRL Never Sleeps

{

of the past. Anabolic and androgenic steroids,
synthetic forms of the male hormone testosterone,
have been used to create fitter, powerful and more
aggressive horses. Corticosteroids (e.g., prednisone
and dexamethasone), on the other hand, generally
are used to relieve inflammation in joints and in
the airways of racehorses. Equine athletes are not
allowed to receive either type of steroid within
24 hours of a race (the exception is in Florida,
where horses can receive the corticosteroid
prednisolone on race day). The Racing Medication
and Testing Consortium (RMTC), founded
in 2000 and governed by a board of directors
consisting of 23 racing-industry stakeholder groups
(including the American Association of Equine
Practitioners and the National Thoroughbred
Racing Association), has developed a model rule
regulating use of anabolic steroids in racehorses.
To date, 24 states (including Pennsylvania, the first
to go steroid free) have adopted the model rule,
and nine states are in the process of doing so.
Again a pioneer, PETRL was the first laboratory
in the world to develop a method of screening,
quantifying and confirming the anabolic steroids
in plasma. Making the switch from urine to
plasma for screening and confirming the presence
of anabolic steroids made it more rapid and cost
effective. “Everyone was testing urine because
it’s a lot easier to get a lot more urine from the
horse,” said Dr. Uboh. “But if you’re really
looking for the action of the drug, it’s not what
is in urine; what it is in plasma matters. If it is
in urine, the body is sending it out, it doesn’t
want it. If it’s in plasma—in the blood—then
it most likely had an effect on the horse.
“Plasma is also cleaner,” Dr. Uboh continued.
“When you look at the urine result, there are
so many peaks/signals, so many other naturally
occurring substances represented by the many
signals observed. With plasma, it’s very clean.
If a drug is present, you see one single signal.
And then you tackle that signal and find an

PETRL scientists process 60,000 samples a
year—equine samples for research, post-race
and pre-race, as well as from human drivers
and trainers and occasional “specials” (e.g., if
a horse expected to win loses, and vice versa,
or retesting positives from other laboratories).
Each positive result helps build PETRL’s own
database of specific drug “fingerprints,” which
now numbers in the hundreds. Truly, Dr. Uboh
and his laboratory colleagues have almost singlehandedly rescued the integrity of the horseracing
industry—in Pennsylvania and beyond.

“We did some screening in 2005, and 60
percent of the horses running in Pennsylvania
had an anabolic steroid in them; some had two
or three different anabolic steroids,” Dr. Soma
remembered. In 2008, the Pennsylvania Horse
Racing Commission and Pennsylvania Harness
Racing Commission collected 2,061 samples
during the first two months of the year 2008;
results showed 98.8 percent of the samples
were negative, according to the governor’s
office. Currently all horses in Pennsylvania
are competing anabolic-steroid–free.
“People think [horseracing] is a very dirty
industry, nothing but drugs, but that’s not true,”
said Dr. Uboh. “We know that only about 0.1
percent test positive. It’s a very clean industry.
Very well regulated, believe me. Horses are very
intensely tested. We don’t leave stones unturned.
Whenever we see something, we pursue it down.”
It is only fitting that such groundbreaking
work takes place in this commonwealth.
“Pennsylvania has a proud history of horseracing
reaching back to the earliest colonists,” said

Dr. Corinne R. Sweeney, associate dean of
Penn Vet’s New Bolton Center campus and
chief operating officer and executive director
for the George D. Widener Hospital for Large
Animals. She currently serves as chair of the
Pennsylvania Horse Racing Commission.
“Pennsylvania’s horse- and harness-racing
industries are the backbone of our state’s
$1.5-billion equine industry,” Dr. Sweeney
continued. “In 1967, the Pennsylvania Horse
Racing Commission was established, and since then
Penn Vet has been there, advising the commission
on issues associated with generating a healthier
racehorse and implementing a safer racing product.
“Because of the work of Drs. Soma and Uboh,
the Pennsylvania Horse Racing Commission
implemented the first ban on anabolic steroids in
the country, which soon was followed by other
major racing jurisdictions,” said Dr. Sweeney.
“The commission continues to turn to these
Penn scientists to guide us as we eliminate the
future use of other drugs in the hope to reduce
catastrophic and lesser racing injuries.”

Dr. Soma with Dr. Cornelius E. Uboh. Photo by Sabina Louise Pierce.
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